U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Drug Development Tool (DDT) Qualification Programs
  5. Additional Drug Development Tool Resources
  1. Drug Development Tool (DDT) Qualification Programs

Additional Drug Development Tool Resources

Additional resources are described below that may be informative in your exploration of drug development tools.

Critical Path Innovation Meetings

Critical Path Innovation Meetings (CPIMs):  A meeting with CDER to discuss a proposed methodology or technology and obtain general advice from CDER on how this methodology or technology might enhance drug development. Other FDA centers participate in CPIM meetings when cross-cutting issues arise that involve a broader audience.

Through this program, FDA expects to become more familiar with prospective innovations in drug development, broadening its regulatory perspective. The discussions and background information submitted through the CPIM are drug1 product-independent and are nonbinding for both the FDA and CPIM requestors.

Other Resources

Over the past several years, FDA has engaged with external stakeholders to develop resources that can be utilized to bring efficiency into the overall drug development and regulatory processes. Examples of such resources are:

Return to Drug Development Tools (DDTs)


1The term drug refers to both human drugs and biological products unless otherwise specified.